2025-08-08 - Analysis Report
Okay, here's an analysis of TG Therapeutics Inc. (TGTX) based on the data you provided.

## TG Therapeutics Inc. (TGTX) Analysis

**Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

### 1. Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 55.77%
*   **VOO Cumulative Return:** 82.59%
*   **Absolute Divergence:** -27.1 (TGTX is 27.1% behind VOO)
*   **Relative Divergence:** 14.6 (Indicates TGTX's divergence is in the lower range of its historical divergence, suggesting it has underperformed relative to its historical range)

**Analysis:** TGTX has underperformed the S&P 500 (VOO) significantly. The relative divergence suggests that this underperformance is relatively large compared to its historical performance.

**Alpha, Beta Analysis:**

| Year        | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
| ----------- | ------- | ------ | ------- | ------ | ------ |
| 2015-2017   | -2.0%   | 2.0%   | -4.0%   | -1.4   | 1.3    |
| 2016-2018   | -54.0%  | 58.7%  | -50.0%  | -0.0   | 0.7    |
| 2017-2019   | 32.0%   | 58.7%  | 10.0%   | -0.0   | 1.8    |
| 2018-2020   | 424.0%  | 58.7%  | 397.0%  | -0.0   | 8.3    |
| 2019-2021   | 132.0%  | 63.5%  | 83.0%   | -0.0   | 3.0    |
| 2020-2022   | -84.0%  | 70.4%  | -91.0%  | 0.0    | 1.9    |
| 2021-2023   | -380.0% | 70.4%  | -400.0% | -0.7   | 2.7    |
| 2022-2024   | 72.0%   | 73.1%  | 45.0%   | -0.8   | 4.8    |
| 2023-2025   | 57.0%   | 73.1%  | 10.0%   | -0.0   | 4.4    |

*   **CAGR:**  Highly variable, indicating inconsistent growth.
*   **MDD:** High Maximum Drawdown values suggest significant risk and volatility.
*   **Alpha:**  The Alpha values are extremely volatile.
*   **Beta:**  Beta values close to zero indicate a very low correlation with the overall market (S&P 500). Negative Beta values are unusual and would suggest that the stock tends to move in the opposite direction to the market, though these values are very small and may not be statistically significant.
*   **Cap(B):** Market Cap fluctuates, showing periods of growth and decline.

**Analysis:** TG Therapeutics has historically shown periods of high growth (e.g., 2018-2020), but also significant declines (e.g., 2021-2023). This instability highlights the speculative nature of the stock.

### 2. Recent Price Action

*   **Current Price:** 27.89
*   **Previous Close:** 27.7
*   **Change:** 0.69
*   **5-day Moving Average:** 29.546
*   **20-day Moving Average:** 35.3272
*   **60-day Moving Average:** 35.9456

**Analysis:** The current price is below all moving averages, which is generally considered a bearish signal. The price is slightly up from the previous close, which shows that the market is trying to recover from the recent fall.

### 3. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.3318 (Low Risk)
*   **RSI:** 12.83 (Oversold)
*   **PPO:** -3.2187
*   **Hybrid Signal:**  Cash 66% Sell 5.6% of holdings (122 shares - Caution - MRI:0.34)
*   **Recent (20-day) Relative Divergence Change:** 0.2 (+, Short-term increase)
*   **Expected Return:** -240.5%

**Analysis:**

*   **MRI:**  Suggests a low level of overall market risk, despite the volatility in TGTX.
*   **RSI:** The extremely low RSI indicates that the stock is heavily oversold. This could suggest a potential for a short-term bounce, but doesn't guarantee it.
*   **PPO:** Negative PPO indicates that the short-term moving average is below the long-term moving average, confirming the downward trend.
*   **Hybrid Signal:** The signal indicates to move into cash, reducing exposure to the stock.
*   **Relative Divergence Change:** A short-term increase in relative divergence suggests a short-term increase in the stock price.
*   **Expected Return:** The extremely negative expected return suggests that, based on the model, long-term investment in TGTX is not expected to outperform the S&P 500.

The small increase in price relative to the previous close does not significantly alter the overall negative outlook.

### 4. Recent News & Significant Events

*   **2025-08-08:** Major business developments, regulatory changes, or market events.
*   **2025-08-07:** Analyst discussions on recent performance, industry trends, and global economic factors.
*   **2025-08-06:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-08-05:** Market experts highlight both risks and opportunities, advising monitoring of recent news and announcements.

**Analysis:**  The news indicates recent volatility and significant events affecting the stock.  The mentions of regulatory changes, earnings reports, and analyst discussions suggest that investors should closely monitor upcoming announcements and news releases to understand the potential direction of the stock.

### 5. Recent Earnings Analysis

| 날짜         | EPS    | 매출      |
| ----------- | ------ | -------- |
| 2025-05-09   | 0.03   | 0.12 B$  |
| 2024-11-07   | 0.03   | 0.08 B$  |
| 2024-08-09   | 0.05   | 0.07 B$  |
| 2024-05-06   | -0.07  | 0.06 B$  |
| 2025-05-09 | -0.07 | 0.06 B$ |

**Analysis:**

*   EPS is inconsistent, fluctuating between positive and negative values. This indicates difficulty in achieving consistent profitability.
*   Revenue shows moderate growth but is not necessarily translating into consistent earnings.

The fluctuating EPS, combined with revenue growth, could indicate increasing operational efficiency but also inherent risks in the company's business model.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
| ---------- | ---------- | ------------- |
| 2025-03-31 | $0.12B    | 87.14%        |
| 2024-12-31 | $0.11B    | 85.77%        |
| 2024-09-30 | $0.08B    | 88.86%        |
| 2024-06-30 | $0.07B    | 88.70%        |
| 2024-03-31 | $0.06B    | 91.43%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE       |
| ---------- | ---------- | --------- |
| 2025-03-31 | $0.24B    | 2.13%     |
| 2024-12-31 | $0.22B    | 10.49%    |
| 2024-09-30 | $0.19B    | 2.02%     |
| 2024-06-30 | $0.18B    | 3.87%     |
| 2024-03-31 | $0.16B    | -6.69%    |

**Analysis:**

*   **Revenue:** Shows an upward trend, indicating growth in sales.
*   **Profit Margin:** High profit margins suggest good cost control and pricing strategies.
*   **Equity:** Increasing equity indicates strengthening of the company's financial base.
*   **ROE:** Fluctuating ROE reflects variability in profitability relative to equity, indicating inconsistencies in generating returns from shareholders' investments.

The combination of growing revenue, high profit margins, and increasing equity is positive, but the fluctuating ROE suggests inherent risks and variability in profitability.

### 7. 종합 분석 (Overall Analysis)

TG Therapeutics Inc. presents a mixed picture.

*   **Bearish Signals:** TGTX has underperformed the S&P 500 and demonstrates significant historical volatility. Current technical indicators such as the RSI and PPO indicate an oversold condition and a continuing downward trend.  The significantly negative expected return is a major concern.
*   **Positive Signals:** Revenue and equity have been increasing.
*   **Catalysts to Watch:** Recent news highlights the importance of monitoring upcoming announcements and events that could significantly influence the stock price.

**Recommendation:**  Given the strong bearish signals, the high volatility, and the underperformance relative to the market, a cautious approach is warranted. The "Hybrid Signal" recommending moving to cash further supports this caution.
